Invacare Corporation Announces Additional Draw of Term Loans and Exchange of Existing Convertible Notes

Rhea-AI Summary

Invacare Corporation (NYSE:IVC) has announced the completion of additional draws totaling $18.5 million of term loans under its Credit Agreement with Highbridge Capital Management. The company still has $19.5 million in additional commitments available, pending certain conditions. Additionally, Invacare swapped $13.825 million in 4.25% Convertible Senior Notes for $10.369 million in 5.68% Convertible Senior Secured Notes due 2026. More details will be provided in a forthcoming Current Report on Form 8-K.

Positive

• Completion of additional draws totaling $18.5 million under the Credit Agreement enhances liquidity.
• Availability of an additional $19.5 million in committed funding, pending conditions.

Negative

• The reliance on convertible notes may indicate financial pressure.
• The need for additional loans may raise concerns about long-term financial stability.

ELYRIA, Ohio--(BUSINESS WIRE)-- Invacare Corporation (NYSE:IVC) (“Invacare” or the “company”) announced today the consummation of additional draws of an aggregate of $18,500,000 of term loans pursuant to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC (“Highbridge”). Additional commitments of $19,500,000 remain available under the Amended Highbridge Loan Agreement, subject to the satisfaction of certain conditions set forth therein.

Concurrently with the additional draws, the company consummated the additional closings under the exchange agreements previously entered into with Highbridge and exchanged $13,825,000 in aggregate principal amount of 4.25% Convertible Senior Notes due 2026 for (i) $5,186,000 in aggregate principal amount of additional 5.68% Convertible Senior Secured Notes due 2026, Tranche I, and (ii) $5,183,000 in aggregate principal amount of additional 5.68% Convertible Senior Secured Notes due 2026, Tranche II.

The transactions described herein are further described in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission. The descriptions herein are qualified in their entirety by reference to the further descriptions to be included in the Current Report on Form 8-K.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The 5.68% Convertible Senior Secured Notes due 2026 and the company’s common shares that may be issuable upon conversion of such notes have not been registered under the Securities Act, or the securities laws of any other jurisdiction and, unless so registered, may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and any applicable state securities laws.

About Invacare Corporation

Invacare Corporation (NYSE:IVC) (“Invacare” or the “company”) is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest, and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company’s products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. The company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, distributors and government health services in North America, Europe, and Asia/Pacific. For more information about the company and its products, visit Invacare’s website at www.invacare.com.

This press release contains forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that describe future outcomes or expectations that are usually identified by words such as “will,” “should,” “could,” “plan,” “intend,” “expect,” “continue,” “forecast,” “believe,” and “anticipate” and include, for example, statements related to the company’s ability to address on-going supply chain challenges; sales and free cash flow trends; the impact of contingency plans and cost containment actions; the company’s liquidity and working capital expectations; the company’s future financial results; and similar statements. Actual results may differ materially as a result of various risks and uncertainties, including the duration and scope of the COVID-19 pandemic, the pace of resumption of access to healthcare, including clinics and elective care, and loosening of public health restrictions, or any reimposed restrictions on access to healthcare or tightening of public health restrictions and impact on the demand for the company’s products; the availability and cost to the company of needed raw materials and components from its suppliers; actions that governments, businesses and individuals take in response to the pandemic, including mandatory business closures and restrictions on onsite commercial interactions; the impact of the pandemic and actions taken in response to the pandemic on global and regional economies and economic activity; the pace of recovery when the COVID-19 pandemic subsides; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; the effects of steps the company has taken or will take to reduce operating costs; the ability of the company to sustain profitable sales growth, achieve anticipated improvements in segment operating performance, convert high inventory levels to cash or reduce its costs; lack of market acceptance of the company’s new product innovations, revised product pricing and/or product surcharges; circumstances or developments that may make the company unable to implement or realize the anticipated benefits, or that may increase the costs, of its current and planned business initiatives, in particular the key elements of its enhanced transformation and growth plan such as its new product introductions, commercialization plans, additional investments in sales force and demonstration equipment, product distribution strategy in Europe, supply chain actions and global information technology outsourcing and ERP implementation activities; possible adverse effects on the company’s liquidity, including the company’s ability to address future debt maturities; adverse changes in government and third-party payor reimbursement levels and practices in the U.S.; adverse impacts of new tariffs or increases in commodity prices or freight and logistics costs; regulatory proceedings or the company’s failure to comply with regulatory requirements or receive regulatory clearance or approval for the company’s products or operations; adverse effects of regulatory or governmental inspections of the company’s facilities at any time and governmental investigations or enforcement actions; exchange rate fluctuations; and those other risks and uncertainties expressed in the cautionary statements and risk factors in the company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The company may not be able to predict and may have little or no control over many factors or events that may influence its future results and, except as required by law, shall have no obligation to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221001005030/en/

Lois Lee

loislee@invacare.com

440-329-6435

Source: Invacare Corporation

FAQ

What is the recent loan announcement by Invacare Corporation (IVC)?

Invacare announced $18.5 million in additional term loans under its Credit Agreement with Highbridge Capital.

How much funding remains available for Invacare under the loan agreement?

Invacare has an additional $19.5 million in funding commitments available, subject to specific conditions.

What notes did Invacare exchange in the recent transaction?

Invacare exchanged $13.825 million of 4.25% Convertible Senior Notes for $10.369 million in 5.68% Convertible Senior Secured Notes.

Where can I find more details about Invacare's recent financial actions?

Further details will be included in Invacare's upcoming Current Report on Form 8-K.